112th CONGRESS
1st Session
H. R. 1254

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.


_______________________________________________________________________


IN THE HOUSE OF REPRESENTATIVES

March 30, 2011

Mr. Dent (for himself, Mr. Meehan, Mr. Marino, Mr. Platts, Mr. Barletta, Mr. Cuellar, Mrs. Emerson, Mrs. Biggert, Mr. LaTourette, Mr. Gibson, Mr. Stivers, and Mr. Reed) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

A BILL



To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Synthetic Drug Control Act of 2011''.

SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT.

(a) Cannabimimetic Agents.--Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:
``(d)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
``(2) In paragraph (1), the term `cannabimimetic agents'--
``(A) means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within the following structural classes:
``(i) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
``(ii) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.
``(iii) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
``(iv) 1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
``(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.; and
``(B) includes--
``(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);
``(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);
``(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678 );
``(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-073);
``(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);
``(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
``(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
``(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
``(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
``(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398 );
``(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
``(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
``(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4);
``(xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8 ); and
``(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
(b) Other Drugs.--Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:
``(18 ) 4-methylmethcathinone (Mephedrone).
``(19) 3,4-methylenedioxypyrovalerone (MDPV).
``(20) 3,4-methylenedioxymethcathinone (methylone).
``(21) Naphthylpyrovalerone (naphyrone).
``(22) 4-fluoromethcathinone (flephedrone).
``(23) 4-methoxymethcathinone (methedrone; Bk-PMMA).
``(24) Ethcathinone.
``(25) 3,4-methylenedioxyethcathinone (ethylone).
``(26) Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone).
``(27) N,N-dimethylcathinone (metamfepramone).
``(28 ) Alpha-pyrrolidinopropiophenone (alpha-PPP).
``(29) 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).
``(30) 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP).
``(31) Alpha-pyrrolidinovalerophenone (alpha-PVP).
``(32) 6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-6-amine) (MDAI).

SECTION 1. SHORT TITLE.

(a) Short Title- This Act may be cited as the ‘Combating Designer Drugs Act of 2011’.

SEC. 2. CONTROLLED SUBSTANCES ACT.

Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:

‘(18 ) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).
‘(19) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).
‘(20) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).
‘(21) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I).
‘(22) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2).
‘(23) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4).
‘(24) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).
‘(25) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).
‘(26) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P).